Bli medlem
Bli medlem

Du är här


Oasmia issues new shares for acquiring an asset corresponding to SEK 25 million

ng an asset corresponding to SEK 25 million

Uppsala, Sweden, October 24, 2016 -- Oasmia Pharmaceutical AB (publ) (“Oasmia”
or the “Company”) hereby announces that the Company has made an offset issue of
3,080,000 new shares in order to pay a purchase price of SEK 25 million
pursuant to an agreement on the acquisition of a cancer project from Karo

Uppsala, Sweden, 2016-10-24 12:15 CEST (GLOBE NEWSWIRE) --

As previously announced on October 24 2106 has Oasmia acquired a novel cancer
project which was paid for by 3,080,000 newly issued shares at a share price of
approximately SEK 8.12 per share

In order to enable the transaction, the Board of Directors of Oasmia has,
pursuant to the authorization granted by the annual general meeting held on
September 26, 2016, resolved on a directed issue of 3,080,000 new shares.

Through the issue, the number of shares in Oasmia increases by 3,080,000 from
115,959,310 to 119,039,310 and the share capital increases by SEK 308,000 from
SEK 11,595,931 to SEK 11,903,931. The new issue results in an equity dilution
of approximately 2.6 percent after the issue is completed.

The information above has been made public in accordance with the Securities
Market Act and the Financial Instruments Trading Act.

Notes to editors:

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new
generations of drugs in the field of human and veterinary oncology. The
company’s product development aims to create and manufacture novel nanoparticle
formulations and drug-delivery systems based on well-established cytostatics
which, in comparison with current alternatives, show improved properties,
reduced side-effects, and expanded applications. The company’s product
development is based on its proprietary in-house research and company patents.
Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange
(OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

Issuance, publication or distribution of this press release in certain
jurisdictions could be subject to restrictions. The recipient of this press
release is responsible for using this press release and the constituent
information in accordance with the rules and regulations prevailing in the
particular jurisdiction. This press release does not constitute an offer or an
offering to acquire or subscribe for any Oasmia Pharmaceutical AB (publ)
securities in any jurisdiction, neither from Oasmia Pharmaceutical AB (publ)
nor anyone else.

Julian Aleksov
Tel: +46 18 50 54 40

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.